Literature DB >> 10763920

Oral administration of muscle derived small molecules inhibits tumor spread while promoting normal cell growth in mice.

S Bar-Yehuda1, T Farbstein, F Barer, G Ohana, P Fishman.   

Abstract

Tumor metastases are extremely rare in striated muscles. This is surprising given the fact that this tissue constitutes 60% of body weight. The present study focuses on small molecules produced and secreted by muscle cells which possess anti-cancer activity in vivo. Recently we have shown that a low molecular weight fraction (< 1000 Dalton) of skeletal muscle cell conditioned medium (muscle factor-MF), markedly inhibits the proliferation of carcinoma, sarcoma or melanoma cell lines in vitro. The MF exerts a cytostatic effect on tumor cell growth and arrests the cells in the G0/G1 of the cell cycle. However, normal cell proliferation, such as bone marrow and fibroblasts, was stimulated following incubation with MF. In this study, the effect of orally administered MF on melanoma and sarcoma growth was examined in mice. The administration of MF to mice inoculated intravenously with melanoma (B16-F10) or sarcoma (MCA-105) cells, resulted in a statistically significant inhibition of metastatic lung foci. In a different model, melanoma was induced in the foot pad and after development of a local lesion, the leg was amputated. A prolonged survival time was observed in the MF treated groups. Since the MF stimulated bone marrow cell proliferation in vitro, we decided to test its efficacy as an inhibitor of the myelotoxic effect exerted by chemotherapy, in vivo. MF, administered after chemotherapy, restored the number of white blood cells and yielded an increased percentage of neutrophils compared with the decline in these parameters after administration of chemotherapy alone. Thus, it is indicated that MF exerted a systemic anti tumor and chemoprotective effect when given orally. It can be concluded that it is bioavailable and is not biodegradable in the digestive system. MF may be considered as a potential therapy for the prevention of tumor spread.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10763920     DOI: 10.1023/a:1006649617918

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  18 in total

1.  Effect of cyclic polylactates on tumor cells and tumor bearing mice.

Authors:  S Takada; Y Nagato; M Yamamura
Journal:  Biochem Mol Biol Int       Date:  1997-09

2.  Various human hematopoietic growth factors (interleukin-3, GM-CSF, G-CSF) stimulate clonal growth of nonhematopoietic tumor cells.

Authors:  W E Berdel; S Danhauser-Riedl; G Steinhauser; E F Winton
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

3.  Carcinoma of the lung occurring as a skeletal muscle mass.

Authors:  A E Pellegrini
Journal:  Arch Surg       Date:  1979-04

4.  Intramyofiber metastasis in skeletal muscle.

Authors:  D P Sarma; T G Weilbaecher; G L Love
Journal:  J Surg Oncol       Date:  1985-10       Impact factor: 3.454

5.  Muscle cells produce a low molecular weight factor with anti-cancer activity.

Authors:  M Djaldetti; B Sredni; R Zigelman; M Verber; P Fishman
Journal:  Clin Exp Metastasis       Date:  1996-05       Impact factor: 5.150

Review 6.  Growth factors in skeletal muscle regeneration.

Authors:  I Husmann; L Soulet; J Gautron; I Martelly; D Barritault
Journal:  Cytokine Growth Factor Rev       Date:  1996-10       Impact factor: 7.638

7.  Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle.

Authors:  J B Kurek; S Nouri; G Kannourakis; M Murphy; L Austin
Journal:  Muscle Nerve       Date:  1996-10       Impact factor: 3.217

8.  Physical activity and the risk of breast cancer.

Authors:  I Thune; T Brenn; E Lund; M Gaard
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

9.  Regulation of matrix metalloproteinases and plasminogen activator inhibitor-1 synthesis by plasminogen in cultured human vascular smooth muscle cells.

Authors:  E Lee; D E Vaughan; S H Parikh; A J Grodzinsky; P Libby; M W Lark; R T Lee
Journal:  Circ Res       Date:  1996-01       Impact factor: 17.367

10.  Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth.

Authors:  P Fishman; S Bar-Yehuda; L Vagman
Journal:  Cancer Res       Date:  1998-07-15       Impact factor: 12.701

View more
  4 in total

1.  In vitro and in vivo studies on the inhibitory effects of myocardial cell culture medium on growth of a human lung adenocarcinoma cell line, A549.

Authors:  Y Zheng; J Zhou; S Z Fu; J Fan; J B Wu
Journal:  Curr Oncol       Date:  2016-02-18       Impact factor: 3.677

2.  Resistance of muscle to tumor metastases: a role for a3 adenosine receptor agonists.

Authors:  S Bar-Yehuda; F Barer; L Volfsson; P Fishman
Journal:  Neoplasia       Date:  2001 Mar-Apr       Impact factor: 5.715

3.  Myogenic cell proliferation and generation of a reversible tumorigenic phenotype are triggered by preirradiation of the recipient site.

Authors:  Jennifer E Morgan; Jacqueline G Gross; Charles N Pagel; Jonathan R Beauchamp; Ariberto Fassati; Adrian J Thrasher; James P Di Santo; Ivan B Fisher; Xu Shiwen; David J Abraham; Terence A Partridge
Journal:  J Cell Biol       Date:  2002-05-13       Impact factor: 10.539

4.  Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101.

Authors:  G Ohana; S Bar-Yehuda; A Arich; L Madi; Z Dreznick; L Rath-Wolfson; D Silberman; G Slosman; P Fishman
Journal:  Br J Cancer       Date:  2003-10-20       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.